4981-83-3 Usage
Description
Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate, also known as Benzyl-PEG2-Tos, is a PEG linker with an acid-labile benzyl protecting group and a 4-methylbenzenesulfonate (tosyl) group as a good leaving group. The hydrophilic PEG linker enhances the water solubility of the compound in aqueous solutions, making it a versatile molecule for various applications.
Uses
Used in Pharmaceutical Industry:
Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as a protecting group for [application type] in the pharmaceutical industry for [application reason] the acid-labile benzyl group, which can be selectively removed under acidic conditions, allowing for controlled drug release or activation.
Used in Drug Delivery Systems:
In the field of drug delivery, Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as a component of drug conjugates for [application reason] its ability to improve the solubility and stability of drugs in aqueous environments. The tosyl group serves as a linker that can be cleaved under specific conditions, enabling targeted drug release.
Used in Chemical Synthesis:
Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as an intermediate in chemical synthesis for [application reason] its functional groups, which can be utilized in various reactions to produce a range of compounds with different properties and applications.
Used in Research and Development:
In research and development, Ethanol, 2-(phenylmethoxy)-, 4-methylbenzenesulfonate is used as a model compound for [application reason] studying the effects of PEGylation on the properties and behavior of molecules, as well as for developing new methods and techniques in chemical synthesis and drug delivery.
Check Digit Verification of cas no
The CAS Registry Mumber 4981-83-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,9,8 and 1 respectively; the second part has 2 digits, 8 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 4981-83:
(6*4)+(5*9)+(4*8)+(3*1)+(2*8)+(1*3)=123
123 % 10 = 3
So 4981-83-3 is a valid CAS Registry Number.
4981-83-3Relevant articles and documents
Formation of ether-functionalized ionic-liquid-based aqueous two-phase systems and their application in separation of protein and saccharides
Wang, Zhijun,Pei, Yuanchao,Zhao, Jing,Li, Zhiyong,Chen, Yujuan,Zhuo, Kelei
, p. 4471 - 4478 (2015)
Ionic-liquid (IL)-based aqueous two-phase systems (ATPSs) have attracted much attention in the separation technology. In this work, we synthesized five novel ether-functionalized ILs and studied their applications in ATPS formation. The phase diagrams for
3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
-
Paragraph 1871-1872, (2020/02/05)
The present disclosure provides a compound of Formula (I′): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein Rx, X1, X2, and R1 are as defined herein, and methods of making and using same.
MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE
-
Paragraph 00778-00779, (2019/10/29)
The present disclosure relates to bifunctional compounds, which find utility as modulators of Kirsten rat sarcoma protein (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation, accumulation, and/or overactivation of the target protein are treated or prevented with compounds and compositions of the present disclosure.